CRL Director James C Foster Sells $8.4M of Stock

By TradeTexts Research Desk Oct 26, 2026, 5:01 PM EDT

Key Points

James C Foster, a Director at Charles River Laboratories, sold 24,042 shares at a price of $350 each, totaling $8,414,700.
Following this trade, Foster owns 31,596 shares, cutting his stake by about 43.21%.
As of October 26, 2026, Charles River Laboratories shares traded recently around $345.37, up about 1.7% since the sale.

Since the trade, $CRL is up 1.7% to date (from the $339.66 close on Oct 22, 2026).

Get Charles River Laboratories International text alerts

We text you when insiders, Congress, analysts or big funds move on $CRL.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Charles River Laboratories International, Inc. alert may contain errors. Disclosures

James C Foster, a Director at Charles River Laboratories International, Inc. (CRL), sold 24,042 shares on October 22, 2026, for a total of $8,414,700. The sale price was $350 per share, while the stock closed at $339.66 on the same day, according to his Form 4 filing with the SEC.

Foster's sale reduced his holdings by about 43.21%, leaving him with 31,596 shares after the transaction. This is a significant change in his ownership, reflecting a planned sale under a Rule 10b5-1 plan.

CRL Charles River Laboratories International, Inc.

$345.37 +70.62% year to date

Daily close · Oct 23, 2026

Insider trading track record

James C Foster vs. the S&P 500

YTD return +73.42% hypothetical

All-time return +108.59% S&P 500 +52.36%

vs. S&P 500 +56.23% ahead of the index

Hypothetical returns from James C Foster's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Charles River Laboratories

Earnest Partners reduced its stake by 16,893 shares, now holding 971,366 shares worth about $220.3 million. Gotham Asset Management increased its holdings by 68,986 shares to 358,502 shares valued at $67.4 million. Harris Associates L.P. added 87,854 shares, bringing its total to 2,241,144 shares worth approximately $800.7 million. Allspring Global Investments Holdings, LLC trimmed its position by 88,106 shares, ending with 1,905,247 shares valued at about $680.7 million. Ariel Investments, LLC increased its stake by 61,957 shares to 1,506,185 shares worth around $538.1 million.

Charles River Laboratories International, Inc. Stock Up 1.7%

As of October 26, 2026, Charles River Laboratories shares traded recently around $345.37, which is about 1.7% above the closing price of $339.66 on the day of Foster's sale. The stock has been performing well, trading above its 50-day moving average by 17.5% and its 200-day moving average by 58.3%. However, it is still slightly below its 52-week high of $351.21.

Recent Earnings

Charles River Laboratories reported trailing twelve-month revenue of approximately $4.00 billion, but its earnings per share (EPS) was negative at -$4.8. The company is set to announce its next earnings on November 4, 2026.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

C+ 66/100

Reported May 7, 2026

Forward outlook
2 analysts raised price targets.
EPS & revenue
EPS beat estimates by 5.0%. Revenue beat estimates by 0.9%.
Profit surprise
EBITDA missed by 6 percent. Operating income missed by 22 percent.
Pre-earnings setup
Expectations were about average.
Analyst signal
1 upgrade, 2 target raises.
Earnings quality
Gross margin down 4.2 points. Operating margin up 4.5 points. Positive free cash flow.

Earnings Call Summary

Charles River delivered first quarter earnings of $2.06 per share, beating expectations of $1.96, with revenue of about $996 million slightly above consensus. The company faced planned headwinds from animal supply costs and timing issues, but management expressed confidence that these would ease in coming quarters. New CEO Birgit Girshick outlined a strategy called Pathway to Purpose focused on modernizing operations, improving client relationships and driving cost savings of over $100 million this year.

Guidance Charles River reaffirmed full year earnings growth guidance of 5 to 10 percent, expecting around $10.80 to $11.30 in earnings per share. They project significant operating margin expansion of 120 to 150 basis points in 2026, driven mainly by cost savings and completed acquisitions.

Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.

Insider Buying and Selling at Charles River Laboratories International, Inc.

In addition to Foster's recent sale, Shannon M Parisotto, an Officer, sold 2,156 shares on October 21, 2026, for about $742,548 under a planned sale. Earlier, Parisotto also sold 981 shares on October 5, 2026, and 2,039 shares on August 19, 2026.

Analysts Set New Price Targets

On September 25, 2026, Deutsche Bank maintained a Buy rating on Charles River Laboratories with a price target of $320, up from $300. TD Cowen also maintained a Buy rating with a target of $325. Jefferies and Morgan Stanley both maintained Buy and Overweight ratings, respectively, with price targets of $340.

About Charles River Laboratories

Charles River Laboratories International, Inc. offers services for drug discovery and development, including safety testing. They serve clients globally and produce research models. This recent insider activity may indicate shifts in confidence among company leadership as they navigate market conditions.

Bottom Line

Investors should watch for Charles River Laboratories' upcoming earnings report on November 4, 2026, for insights into its financial health. The recent insider trades reflect significant movements in ownership, and further filings may reveal more about the company's strategic direction.